Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration

Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2014, Pages 282-290

  Greenblatt, David J ^a   Harmatz, Jerold S ^a   Singh, Nikhilesh N ^b   Steinberg, Frank ^b   Roth, Thomas ^c   Moline, Margaret L ^d   Harris, Stephen C ^d   Kapil, Ram P ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Transcept Pharmaceuticals Inc   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d PURDUE PHARMA L P   (United States)

Author keywords

gender; insomnia; pharmacodynamics; pharmacokinetics; zolpidem sublingual tablet

Indexed keywords

PLACEBO; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MIDDLE AGED; MORNING DOSAGE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SOMNOLENCE; YOUNG ADULT;

GENDER; INSOMNIA; PHARMACODYNAMICS; PHARMACOKINETICS; ZOLPIDEM SUBLINGUAL TABLET;

ADMINISTRATION, SUBLINGUAL; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PYRIDINES; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84898615196     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.220     Document Type: Article

References (40)

1. Soares CN, Murray BJ., Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am. 2006; 29: 1095-1113. (Pubitemid 44751926)
2. Krishnan V, Collop NA., Gender differences in sleep disorders. Curr Opin Pulm Med. 2006; 12: 383-389. (Pubitemid 44624595)
3. Zhang B, Wing YK., Sex differences in insomnia: a meta-analysis. Sleep 2006; 29: 85-93. (Pubitemid 44019033)
4. Jaussent I, Dauvilliers Y, Ancelin ML, et al. Insomnia symptoms in older adults: associated factors and gender differences. Am J Geriatr Psychiatry. 2011; 19: 88-97.
5. Ohayon MM., Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 6: 97-111. (Pubitemid 35231066)
6. Peretti-Watel P, Legleye S, Baumann M, et al. Fatigue, insomnia and nervousness: gender disparities and roles of individual characteristics and lifestyle factors among economically active people. Soc Psychiatry Psychiatr Epidemiol. 2009; 44: 703-709.
7. Franconi F, Brunelleschi S, Steardo L, Cuomo V., Gender differences in drug responses. Pharmacol Res. 2007; 55: 81-95. (Pubitemid 46186037)
8. Cotreau MM, von Moltke LL, Greenblatt DJ., The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005; 44: 33-60. (Pubitemid 40100551)
9. Greenblatt DJ, von Moltke LL., Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol. 2008; 48: 1350-1355.
10. Schwartz JB., The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007; 82: 87-96. (Pubitemid 46944201)
11. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF., Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004; 44: 499-523. (Pubitemid 38263851)
12. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. 1996; 276: 370-379. (Pubitemid 126660470)
13. Greenblatt DJ, Zammit GK., Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opin Drug Metab Toxicol. 2012; 8: 1609-1618.
14. Chetty M, Mattison D, Rostami-Hodjegan A., Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab. 2012; 13: 778-786.
15. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI., Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther. 1994; 56: 100-111. (Pubitemid 24251570)
16. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000; 293: 435-443. (Pubitemid 30244092)
17. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI., Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther. 2004; 76: 467-479. (Pubitemid 39469870)
18. Greenblatt DJ, Harmatz JS, Shader RI., Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol. 2011; 31: 1-3.
19. Greenblatt DJ, Roth T., Zolpidem for insomnia. Expert Opin Pharmacother. 2012; 13: 879-893.
20. von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999; 48: 89-97. (Pubitemid 29296668)
21. Greenblatt DJ, Harmatz JS, Roth T, et al. Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. Clin Ther. 2013; 35: 604-611.
22. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003; 56: 297-304. (Pubitemid 37069221)
23. Bianchetti G, Dubruc C, Thiercelin JF, et al. Clinical pharmacokinetics of zolpidem in various psychological and pathological conditions. In:, Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach New York, NY: Raven Press; 1998. p155-163.
24. Verster JC, Roth T., Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev. 2012; 13: 286-292.
25. United States Food and Drug Agency Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Available at http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM335007.pdf. Accessed June 21, 2013.
26. Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB, Intermezzo Study Group. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep. 2008; 31: 1277-1284.
27. Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M., Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013; 36: 189-196.
28. Lankford A., Sublingual zolpidem tartrate lozenge for the treatment of insomnia. Expert Rev Clin Pharmacol. 2009; 2: 333-337.
29. Roth T, Mayleben D, Corser BC, Singh NN., Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol. 2008; 23: 13-20. (Pubitemid 351166064)
30. Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997; 37: 693-703. (Pubitemid 27449278)
31. Roehrs T, Merlotti L, Zorick F, Roth T., Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl). 1994; 116: 130-134. (Pubitemid 24317038)
32. Stone BM., Pencil and paper tests-sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984; 18 (Suppl 1): 15S-20S. (Pubitemid 15184100)
33. Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ., Sedative effects and impaired learning and recall after single oral doses of lorazepam. Clin Pharmacol Ther. 1986; 39: 526-529. (Pubitemid 16113124)
34. Greenblatt DJ, Harmatz JS., Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol. 1993; 13: 231-234. (Pubitemid 23265160)
35. Greenblatt DJ, Gan L, Harmatz JS, Shader RI., Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the digit-symbol substitution test. Br J Clin Pharmacol. 2005; 60: 244-248. (Pubitemid 41224131)
36. Laurijssens BE, Greenblatt DJ., Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 1996; 30: 52-76. (Pubitemid 26030420)
37. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol. 2006; 46: 1469-1480. (Pubitemid 44704207)
38. Salvà P, Costa J., Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995; 29: 142-153.
39. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther. 1998; 64: 553-561. (Pubitemid 28531600)
40. Purdue Pharma L.P. 2013. Intermezzo (zolpidem tartrate tablet). Revised 02/2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist. Accessed July 2, 2013.